Centessa Drops Phase 2 Hemophilia B Drug in Wake of Pfizer's Hympavzi Approval

After Pfizer recently received approval for its tissue factor signaling inhibitor Hympavzi, Centessa Pharmaceuticals has decided that bringing its own hemophilia B competitor to market is not a problem After Pfizer recently received approval for its hemophilia B drug Hympavzi, Centessa Pharmaceuticals has concluded that it is not worth bringing its own competitor to market.